Medroxalol (CAS 56290-94-9)
Alternate Names:
5-[2-[[3-(1,3-Benzodioxol-5-yl)-1-methylpropyl]amino]-1-hydroxyethyl]-2-hydroxybenzamide
CAS Number:
56290-94-9
Molecular Weight:
372.41
Molecular Formula:
C20H24N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Medroxalol is a beta-adrenergic antagonist that functions by blocking the beta-adrenergic receptors in cells. This action inhibits the binding of adrenaline and noradrenaline to these receptors, preventing the activation of the sympathetic nervous system. Medroxalol′s function as a beta-adrenergic antagonist allows for the investigation of the role of adrenergic signaling in various cellular and physiological processes.
Medroxalol (CAS 56290-94-9) References
- Demonstration of the beta 2-adrenoceptor intrinsic efficacy of AY-28,925 using the PGF2 alpha-contracted guinea-pig trachea. | Heaslip, RJ., et al. 1987. Eur J Pharmacol. 137: 179-84. PMID: 2886349
- Antihypertensive aminotetralins related to labetalol and medroxalol. | Clark, RD., et al. 1986. J Pharm Sci. 75: 80-2. PMID: 3007731
- Carcinogenicity studies with medroxalol hydrochloride in rats and mice. | Sells, DM. and Gibson, JP. 1987. Toxicol Pathol. 15: 457-67. PMID: 3432947
- Induction of uterine leiomyomas in mice by medroxalol and prevention by propranolol. | Gibson, JP., et al. 1987. Toxicol Pathol. 15: 468-73. PMID: 3432948
- Intravenous medroxalol stimulates prolactin secretion in normal and hypertensive subjects. | Williams, TC., et al. 1987. Clin Pharmacol Ther. 42: 76-81. PMID: 3595069
- Antihypertensive and vasodilating effects of acute medroxalol, a new beta-blocker with beta-2-adrenergic receptor stimulation. | Simon, A., et al. 1986. J Pharmacol. 17: 331-7. PMID: 3795977
- Salicylamide derivatives related to medroxalol with alpha- and beta-adrenergic antagonist and antihypertension activity. | Grisar, JM., et al. 1981. J Med Chem. 24: 327-36. PMID: 6115059
- Medroxalol combined with hydrochlorothiazide in the treatment of hypertension. | Vlachakis, ND., et al. 1983. J Clin Pharmacol. 23: 419-27. PMID: 6139390
- [Hemodynamic effects of medroxalol in the anesthetized dog. Relation between adrenolytic properties and plasma concentration]. | Weissenburger, J., et al. 1983. J Pharmacol. 14: 413-23. PMID: 6142982
- Analysis of the hypotensive effects of medroxalol and its enantiomers, MDL 17,330A and MDL 17,331A. | Hancock, AA. 1984. Clin Exp Hypertens A. 6: 659-84. PMID: 6144408
- Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties. | Elliott, HL., et al. 1984. Br J Clin Pharmacol. 17: 565-72. PMID: 6145440
- Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. | Elliott, HL., et al. 1984. Br J Clin Pharmacol. 17: 573-8. PMID: 6145441
- Cardiovascular properties of medroxalol, a new antihypertensive drug. | Dage, RC., et al. 1981. J Cardiovasc Pharmacol. 3: 299-315. PMID: 6166802
- Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. | Haegele, KD., et al. 1983. Clin Pharmacol Ther. 34: 785-91. PMID: 6641094
- An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. | van Zwieten, PA. 1993. Drugs. 45: 509-17. PMID: 7684671
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Medroxalol, 25 mg | sc-489407 | 25 mg | $347.00 |